Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.48 -1.3%	$1.31	$0.87 ▼ $6.78	$147.99M	0.71	833,434 shs	2.12 million shs
BHST BioHarvest Sciences	$6.71 -1.3%	$6.61	$4.66 ▼ $7.86	$110.18M	0.59	10,372 shs	3,777 shs
KYTX Kyverna Therapeutics	$3.28 -5.5%	$2.60	$1.78 ▼ $11.40	$141.76M	2.52	383,211 shs	3.72 million shs
QTTB Q32 Bio	$1.45 -6.5%	$1.70	$1.38 ▼ $53.79	$17.69M	-0.04	200,155 shs	928,603 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	+0.68%	+10.04%	+20.33%	-67.40%
BHST BioHarvest Sciences	0.00%	-4.96%	+7.02%	+8.40%	+670,999,900.00%
KYTX Kyverna Therapeutics	0.00%	+6.84%	+30.16%	+69.95%	-56.27%
QTTB Q32 Bio	0.00%	-6.45%	-17.14%	-12.12%	-91.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	3.8352 of 5 stars	3.1	3.0	0.0	4.5	1.4	2.5	0.0
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	1.6617 of 5 stars	3.6	1.0	0.0	0.0	2.2	0.0	0.6
QTTB Q32 Bio	2.7533 of 5 stars	3.1	4.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.14	Hold	$4.00	170.27% Upside
BHST BioHarvest Sciences	3.00	Buy	$13.67	103.68% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	464.02% Upside
QTTB Q32 Bio	2.25	Hold	$12.17	739.08% Upside

Current Analyst Ratings Breakdown

Latest QTTB, ALEC, BHST, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/9/2025	ALEC Alector	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/8/2025	BHST BioHarvest Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/3/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $4.00
4/1/2025	KYTX Kyverna Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $20.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	1.47	N/A	N/A	$1.29 per share	1.15
BHST BioHarvest Sciences	$25.19M	4.37	N/A	N/A	$0.08 per share	83.88
KYTX Kyverna Therapeutics	$7.03M	20.17	N/A	N/A	$6.17 per share	0.53
QTTB Q32 Bio	$1.16M	15.25	N/A	N/A	$0.47 per share	3.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.26	N/A	N/A	N/A	-139.74%	-100.58%	-25.15%	8/6/2025 (Estimated)
BHST BioHarvest Sciences	-$12.91M	-$0.50	N/A	N/A	N/A	-31.30%	-307.04%	-33.21%	8/14/2025 (Estimated)
KYTX Kyverna Therapeutics	-$127.48M	-$3.38	N/A	N/A	N/A	N/A	-51.66%	-45.92%	8/11/2025 (Estimated)
QTTB Q32 Bio	-$47.73M	-$4.94	N/A	N/A	N/A	N/A	-447.33%	-59.77%	8/6/2025 (Estimated)

Latest QTTB, ALEC, BHST, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/8/2025	Q1 2025	QTTB Q32 Bio	-$1.23	-$0.90	+$0.33	-$0.90	N/A	N/A
3/31/2025	Q4 2024	BHST BioHarvest Sciences	-$0.12	-$0.17	-$0.05	-$0.17	$7.24 million	$7.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.10	3.34	3.34
BHST BioHarvest Sciences	N/A	0.51	0.30
KYTX Kyverna Therapeutics	N/A	7.44	7.44
QTTB Q32 Bio	1.68	4.71	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
BHST BioHarvest Sciences	N/A
KYTX Kyverna Therapeutics	18.08%
QTTB Q32 Bio	31.32%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.10%
BHST BioHarvest Sciences	N/A
KYTX Kyverna Therapeutics	N/A
QTTB Q32 Bio	40.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	99.99 million	90.89 million	Optionable
BHST BioHarvest Sciences	N/A	16.42 million	N/A	N/A
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
QTTB Q32 Bio	39	12.20 million	7.32 million	N/A

QTTB, ALEC, BHST, and KYTX Headlines

Recent News About These Companies

Q32 Bio (NASDAQ:QTTB) Stock Rating Upgraded by Wall Street Zen

June 29 at 2:15 AM | americanbankingnews.com

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

June 25, 2025 | prnewswire.com

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025 | prnewswire.com

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

April 30, 2025 | prnewswire.com

Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)

April 18, 2025 | markets.businessinsider.com

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

April 16, 2025 | prnewswire.com

All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy

April 8, 2025 | zacks.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Q32 Bio (QTTB)

March 12, 2025 | markets.businessinsider.com

Q32 Bio price target lowered to $15 from $16 at Wells Fargo

March 12, 2025 | markets.businessinsider.com

Q32 Bio Reports Promising Trial Results and Financials

March 11, 2025 | tipranks.com

Q32 Bio: Q4 Earnings Snapshot

March 11, 2025 | sfgate.com

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

March 11, 2025 | prnewswire.com

Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart

March 10, 2025 | markets.businessinsider.com

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

March 8, 2025 | prnewswire.com

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

February 28, 2025 | prnewswire.com

Q32 Bio to Participate in Upcoming March Investor Conferences

February 26, 2025 | prnewswire.com

Piper Sandler Downgrades Q32 Bio (QTTB)

February 12, 2025 | msn.com

BMO Capital Downgrades Q32 Bio (QTTB)

February 12, 2025 | msn.com

Q32 Bio (NASDAQ:QTTB) Stock Quotes, Forecast and News Summary

February 12, 2025 | benzinga.com

Q32 Bio sticks with bempikibart, but loses staff and phase 2 complement inhibitor

February 11, 2025 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB, ALEC, BHST, and KYTX Company Descriptions

Alector NASDAQ:ALEC

$1.48 -0.02 (-1.33%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.15 +1.67 (+112.84%)

As of 04:00 AM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

BioHarvest Sciences NASDAQ:BHST

$6.71 -0.09 (-1.32%)

As of 06/27/2025 02:45 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Kyverna Therapeutics NASDAQ:KYTX

$3.28 -0.19 (-5.48%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.85 +0.57 (+17.38%)

As of 04:00 AM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Q32 Bio NASDAQ:QTTB

$1.45 -0.10 (-6.45%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.11 (+7.66%)

As of 04:03 AM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time